|
1
|
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
|
J Clin Psychiatry
|
2002
|
1.19
|
|
2
|
Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.
|
Drug Alcohol Depend
|
2008
|
1.08
|
|
3
|
Antipsychotic treatment of psychosis associated with multiple sclerosis.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2004
|
1.07
|
|
4
|
Buprenorphine in the treatment of opioid dependence.
|
Eur Neuropsychopharmacol
|
2004
|
1.03
|
|
5
|
Predictors of relapse in the year after hospital discharge among patients with schizophrenia.
|
Psychiatr Serv
|
2012
|
1.00
|
|
6
|
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
|
Wien Med Wochenschr
|
2010
|
0.99
|
|
7
|
Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.
|
Int Clin Psychopharmacol
|
2010
|
0.96
|
|
8
|
Safety and efficacy of combined clozapine-lithium pharmacotherapy.
|
Int J Neuropsychopharmacol
|
2004
|
0.95
|
|
9
|
The intensity dependence of auditory ERP components in unmedicated patients with major depression and healthy controls. An analysis of group differences.
|
J Affect Disord
|
2007
|
0.94
|
|
10
|
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
|
Int J Neuropsychopharmacol
|
2008
|
0.93
|
|
11
|
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
|
Schizophr Res
|
2009
|
0.92
|
|
12
|
Age-related changes of the dentate nuclei in normal adults as revealed by 3D fast low angle shot (FLASH) echo sequence magnetic resonance imaging.
|
J Neurol
|
2004
|
0.92
|
|
13
|
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.
|
Eur Arch Psychiatry Clin Neurosci
|
2014
|
0.92
|
|
14
|
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
|
Eur Neuropsychopharmacol
|
2011
|
0.89
|
|
15
|
Attention deficit hyperactivity disorder and borderline personality disorder.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2005
|
0.89
|
|
16
|
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy.
|
J Clin Psychopharmacol
|
2008
|
0.88
|
|
17
|
Attitude towards adherence in patients with schizophrenia at discharge.
|
J Psychiatr Res
|
2009
|
0.87
|
|
18
|
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.
|
Int Clin Psychopharmacol
|
2010
|
0.87
|
|
19
|
Concomitant endocrine and immune alterations during alcohol intoxication and acute withdrawal in alcohol-dependent subjects.
|
Neuropsychobiology
|
2002
|
0.86
|
|
20
|
Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI.
|
J Neurol
|
2005
|
0.86
|
|
21
|
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
|
J Clin Psychopharmacol
|
2010
|
0.85
|
|
22
|
Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.
|
Int J Methods Psychiatr Res
|
2005
|
0.84
|
|
23
|
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
|
Psychopathology
|
2012
|
0.83
|
|
24
|
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.
|
Psychiatry Res
|
2008
|
0.83
|
|
25
|
Response trajectories in "real-world" naturalistically treated schizophrenia patients.
|
Schizophr Res
|
2012
|
0.82
|
|
26
|
An early improvement threshold to predict response and remission in first-episode schizophrenia.
|
Br J Psychiatry
|
2010
|
0.82
|
|
27
|
Akathisia and suicidal ideation in first-episode schizophrenia.
|
J Clin Psychopharmacol
|
2012
|
0.82
|
|
28
|
Chronic mu-opioid receptor stimulation alters cardiovascular regulation in humans: differential effects on muscle sympathetic and heart rate responses to arterial hypotension.
|
J Cardiovasc Pharmacol
|
2002
|
0.81
|
|
29
|
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
|
World J Biol Psychiatry
|
2010
|
0.81
|
|
30
|
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
|
J Psychiatr Res
|
2011
|
0.81
|
|
31
|
Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders.
|
Eur Arch Psychiatry Clin Neurosci
|
2007
|
0.80
|
|
32
|
Prediction of symptom remission in schizophrenia during inpatient treatment.
|
World J Biol Psychiatry
|
2009
|
0.80
|
|
33
|
One-year functional outcomes of naturalistically treated patients with schizophrenia.
|
Psychiatry Res
|
2012
|
0.80
|
|
34
|
Psychotropic drug prescription in a psychiatric university hospital in Germany.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2006
|
0.79
|
|
35
|
Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.
|
J Clin Psychopharmacol
|
2003
|
0.79
|
|
36
|
A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2006
|
0.79
|
|
37
|
Urine labeling with orally applied marker substances in drug substitution therapy.
|
Clin Chem Lab Med
|
2004
|
0.78
|
|
38
|
History of attention-deficit hyperactivity disorder symptoms and opioid dependence: a controlled study.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2005
|
0.78
|
|
39
|
Clinical symptoms of major depression are associated with the intensity dependence of auditory event-related potential components.
|
Psychiatry Res
|
2009
|
0.77
|
|
40
|
The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients.
|
Int J Neuropsychopharmacol
|
2006
|
0.77
|
|
41
|
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.
|
Psychiatr Q
|
2012
|
0.77
|
|
42
|
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
|
World J Biol Psychiatry
|
2011
|
0.77
|
|
43
|
Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004.
|
Psychiatr Q
|
2007
|
0.77
|
|
44
|
[Attention-deficit/hyperactivity disorder and substance abuse].
|
Psychiatr Prax
|
2003
|
0.76
|
|
45
|
Neuropsychological assessment of adult patients with attention-deficit/hyperactivity disorder.
|
Eur Arch Psychiatry Clin Neurosci
|
2007
|
0.76
|
|
46
|
[The visit at home by a social worker of a psychiatric outpatient clinic].
|
Psychiatr Prax
|
2004
|
0.75
|
|
47
|
[Descriptive analysis of drug-related deaths over a 5-year period].
|
Psychiatr Prax
|
2003
|
0.75
|
|
48
|
Antidepressant medication and the assimilation of problematic experiences in psychotherapy.
|
Psychother Res
|
2003
|
0.75
|
|
49
|
Sympathetic neural activation evoked by mu-receptor blockade in patients addicted to opioids is abolished by intravenous clonidine.
|
Anesthesiology
|
2002
|
0.75
|
|
50
|
Management of acutely ill patients in the hospital setting: focus on quetiapine.
|
Int J Psychiatry Clin Pract
|
2007
|
0.75
|
|
51
|
Syphilis infection among drug addicts in western Germany.
|
Addiction
|
2002
|
0.75
|
|
52
|
[Escitalopram: a chiral agent for treatment of depression].
|
Med Monatsschr Pharm
|
2004
|
0.75
|